Zynga and Automotive Tuner Liberty Walk Launch One-Of-A-Kind Design Competition for CSR Racing 2’s New Elite Tuners Feature
24.11.2020 17:00:00 EET | Business Wire | Press release
Today, Zynga (Nasdaq:ZNGA), a global leader in interactive entertainment, announced a partnership with Japanese premier car tuner Liberty Walk for the launch of the new Elite Tuners feature and ‘Design A Wrap’ competition in CSR Racing 2 (CSR2).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201124005059/en/
Zynga and Automotive Tuner Liberty Walk Launch One-Of-A-Kind Design Competition for CSR Racing 2’s New Elite Tuners Feature (Photo: Business Wire)
Starting December 9, players can enter the exclusive mobile racing competition by designing a custom car-wrap to be featured in CSR2 and the contest winner will have their design placed onto a real-world Toyota Supra by Liberty Walk. To enter, players will upload their player-designed wraps to social media, tagging @CSRRacing and using the hashtag #CSR2Wrap. Players will be encouraged to like and share their favorite designs.
The top 10 designs selected will be presented to the Liberty Walk team, who will then choose the final winner on February 20, 2021 through a special unveiling of the selected car design. In announcing the partnership, Liberty Walk’s founder Wataru San, along with his team, released a video teasing the new Elite Tuner feature in CSR2.
Elite Tuners is one of the largest customization expansions in CSR2’s history, giving players unprecedented freedom to express their identity with deeper customization such as body kits, spoilers and more. Players can also elevate their performance and add rare cars to their existing collection.
“We’re excited to partner with the iconic Liberty Walk team to deliver the Elite Tuners feature in CSR2 as a best-in-class customization experience for our players across the globe,” said Julian Widdows, Vice President of CSR2. “To have Liberty Walk bring to life a custom car-wrap design is a dream come true for any player. I cannot wait to see the creativity and designs coming from our players.”
“We have collaborated with CSR Racing 2 for quite a few years now,’” said Liberty Walk’s founder Wataru San. “They recreated our body kits the best and respected our design and style. We trust them and it makes me very happy to appear in the game during my own event. We have been doing our best to please ours and CSR2's fans.”
CSR2 is available to download for free on the App Store as well as on Google Play. For more information about CSR2, visit the game’s community channels on Facebook, Instagram, Twitter and YouTube.
To view the supporting assets for CSR2, please click here:
https://www.dropbox.com/sh/iw2xzdy94t2sgw6/AAAgs6JF_NJBY_cVhYTum_z7a?dl=0
ABOUT ZYNGA INC.
Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises including CSR Racing™, Empires & Puzzles™, Merge Dragons!™, Merge Magic!™, Toon Blast™, Toy Blast™, Words With Friends™ and Zynga Poker™. Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with locations in the U.S., Canada, the U.K., Ireland, India, Turkey and Finland. For more information, visit www.zynga.com or follow Zynga on Twitter, Instagram, Facebook or the Zynga blog.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, relating to, among other things, the release of future CSR Racing 2 game features and events. Forward-looking statements often include words such as "outlook," "projected," “planned,” "intends," "will," "anticipate," "believe," "target," "expect," and statements in the future tense are generally forward-looking. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties, and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties, and assumptions are or will be described in greater detail in our public filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained by visiting our Investor Relations website at http://investor.zynga.com or the SEC’s web site at www.sec.gov.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201124005059/en/
Contact information
ZYNGA MEDIA CONTACT
Kenny Johnston
KJohnston@Zynga.com | (602) 999-1890
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom